# psoriasis - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 3982
- Completion tokens: 19913
- Reasoning tokens: 
- Total tokens: 23895
- API requests reported: 
- Elapsed seconds: 218.736
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
## 1. Overall biological interpretation

The input table is a disease-state differential expression analysis: psoriatic lesional skin compared with normal control skin. All listed genes have extremely small FDR values, so the statistical confidence in individual gene-level changes is very high. The biological interpretation, however, depends on integrating these genes into known epidermal and immune biology.

At the broadest level, the psoriatic lesion transcriptome is dominated by a coordinated **keratinocyte–immune amplification program**. The most striking feature is the simultaneous upregulation of:

- **IL-36 and IL-20 family cytokines** — IL36A, IL36G, IL19, IL20, IL26, plus the IL-36 receptor antagonist IL36RN;
- **Antimicrobial peptides and alarmins** — S100A7, S100A7A, S100A8, S100A12, DEFB4A/B, DEFB103A/B, PI3/elafin, TCN1;
- **Cornified envelope and epidermal remodeling genes** — SPRR2A/B/D/E/F/G, SPRR3, LCE3A/D, KRT6A, GJB2/GJB6, SERPINB3/B4/B11/B13, TMPRSS11D, KLK13;
- **Cell-cycle and proliferation genes** — CCNE1, RRM2, CDK5R1, TTC39A;
- **Lipid-metabolizing and phospholipase genes** — PLA2G4D, PLA2G4E, AKR1B10, AKR1B15, FABP5, ABCG4, PLBD1.

This pattern is highly consistent with the established model of psoriasis as an **IL-23/IL-17-driven inflammatory disease with strong IL-36 amplification, neutrophilic inflammation, and regenerative epidermal hyperproliferation**. The downregulated genes are fewer, but they include BTC, CYP2W1, UGT3A2, WAKMAR1, SAPCD1 and several poorly annotated lncRNAs. These may reflect a partial loss of normal epidermal metabolic/differentiation features, but their functional significance is less clear and should be interpreted cautiously.

Importantly, the dataset is from bulk tissue. Therefore, the signal represents a mixture of keratinocytes, infiltrating T cells, neutrophils, dendritic cells, and other skin-resident cells. Some of the strongest signals, such as S100A12, PI3, and TCN1, may partly reflect neutrophil content rather than keratinocyte expression alone.

---

## 2. Core biological programs

### Program 1: IL-36 / IL-20 cytokine amplification and inflammatory feedback

**Direction:** Upregulated

**Supporting genes:**  
IL36A, IL36G, IL36RN, IL19, IL20, IL26, IRAK2, ZC3H12A, TNIP3

**Relevant pathway:**  
Reactome: Interleukin-36 signaling; KEGG: Cytokine–cytokine receptor interaction; Hallmark: Inflammatory response

**Interpretation:**  
IL36A and IL36G are keratinocyte-derived cytokines that activate IL-1 receptor family signaling. IL36RN encodes the IL-36 receptor antagonist and is likely induced as a negative-feedback mechanism. IL19, IL20, and IL26 are IL-20 family cytokines that signal through shared receptor chains and promote keratinocyte proliferation and antimicrobial peptide production. IRAK2 and TNIP3 are involved in TLR/IL-1R/NF-κB signaling and its regulation; ZC3H12A (Regnase-1) is an RNA-binding protein that destabilizes inflammatory mRNAs. Together, these genes suggest a self-amplifying cytokine loop rather than a single cytokine effect.

**Evidence strength:** Strong. Multiple independent genes with extreme FDR support this program, and IL-36/IL-20 activation is well established in psoriasis biology. The major limitation is that bulk tissue cannot show which cells produce these cytokines or whether the feedback arm is successfully restraining inflammation.

---

### Program 2: Antimicrobial peptides, alarmins, and neutrophil recruitment

**Direction:** Upregulated

**Supporting genes:**  
S100A7, S100A7A, S100A8, S100A12, DEFB4A, DEFB4B, DEFB103A/B, PI3, TCN1, CXCR2, HPSE

**Relevant pathway:**  
GO: antimicrobial humoral response; Reactome: Neutrophil degranulation; KEGG: IL-17 signaling pathway

**Interpretation:**  
S100 proteins and β-defensins are antimicrobial peptides/alarmins induced by IL-17 and IL-36 signaling. They are strongly upregulated in psoriatic lesions. PI3 (elafin) and TCN1 are additional epithelial/neutrophil granule-associated proteins. CXCR2 is a chemokine receptor that supports neutrophil recruitment, and HPSE (heparanase) can facilitate leukocyte trafficking through the extracellular matrix. This program is the downstream effector arm of the IL-17/IL-36 axis and is consistent with the neutrophil-rich histology of psoriasis.

**Evidence strength:** Strong. The number of independent gene families is large, and the pattern is biologically coherent. The main limitation is that some of these genes are expressed by neutrophils, so cell-composition effects may contribute.

---

### Program 3: Cornified envelope, keratinocyte differentiation, and barrier remodeling

**Direction:** Upregulated

**Supporting genes:**  
SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, SPRR3, LCE3A, LCE3D, KRT6A, GJB2, GJB6, SERPINB3, SERPINB4, SERPINB11, SERPINB13, TMPRSS11D, KLK13

**Relevant pathway:**  
Reactome: Keratinization; GO: cornified envelope

**Interpretation:**  
SPRRs and LCEs are components of the cornified envelope, a structure normally formed during terminal keratinocyte differentiation. KRT6A is a hyperproliferation-associated keratin. GJB2 and GJB6 encode connexins involved in keratinocyte gap-junction communication. SERPINB3/B4/B11/B13 are serine/cysteine protease inhibitors associated with squamous differentiation; TMPRSS11D and KLK13 are epidermal proteases involved in desquamation and protease signaling. The upregulation of these genes suggests a regenerative, altered differentiation program rather than normal, orderly terminal differentiation.

**Evidence strength:** Strong statistical support and strong known biology. The limitation is that the direction is not simply “barrier loss”: psoriasis involves aberrant differentiation, and these genes may reflect a repair/regenerative response. Spatial localization is needed to confirm cell-layer specificity.

---

### Program 4: Cell-cycle activation and epidermal hyperproliferation

**Direction:** Upregulated

**Supporting genes:**  
CCNE1, RRM2, CDK5R1, TTC39A, BMAL2, TPBG

**Relevant pathway:**  
KEGG: Cell cycle; Reactome: Cell Cycle, G1/S transition

**Interpretation:**  
CCNE1 encodes cyclin E1, which drives G1/S transition. RRM2 encodes the ribonucleotide reductase subunit required for DNA synthesis. CDK5R1 is a regulatory subunit for CDK5; its role in skin is less established than in neuronal tissue, but it has been linked to keratinocyte biology. TTC39A and BMAL2 are less directly tied to proliferation, so this program is supported mainly by CCNE1 and RRM2. Psoriasis is characterized by epidermal hyperplasia, so these genes are consistent with increased keratinocyte proliferation, though they could also reflect proliferating immune cells.

**Evidence strength:** Moderate. The statistical evidence is strong, but the number of highly specific proliferation markers is limited, and cell-source ambiguity remains.

---

### Program 5: Lipid metabolism, phospholipase activation, and eicosanoid-related signaling

**Direction:** Upregulated; some normal metabolic genes downregulated

**Supporting genes:**  
PLA2G4D, PLA2G4E, AKR1B10, AKR1B15, FABP5, ABCG4, PLBD1, KYNU; downregulated: CYP2W1, UGT3A2

**Relevant pathway:**  
KEGG: Arachidonic acid metabolism; GO: lipid metabolic process

**Interpretation:**  
PLA2G4D and PLA2G4E are phospholipase A2 enzymes that can release arachidonic acid and lysophospholipids, precursors for pro-inflammatory eicosanoids. AKR1B10 and AKR1B15 are aldo-keto reductases involved in retinoid and carbonyl metabolism. FABP5 is an epidermal fatty-acid-binding protein. ABCG4 is a lipid transporter. KYNU is a kynurenine-pathway enzyme that may modulate local immune metabolism. The downregulation of CYP2W1 and UGT3A2 suggests suppression of some xenobiotic-metabolizing enzymes. Overall, this program points to active lipid-mediator production and metabolic reprogramming in lesional skin.

**Evidence strength:** Moderate-to-strong for PLA2G4D, which is known to be expressed in psoriatic epidermis. The broader lipid interpretation is plausible but requires direct lipid measurements.

---

## 3. Key genes and interaction modules

The following are the highest-priority genes/modules, selected because they are statistically strong, biologically central, and likely to be useful for validation. Relationships are explicitly labeled.

### 1. IL-36 axis: IL36A, IL36G, IL36RN

- **Direction:** IL36A +11.37, IL36G +5.68, IL36RN +3.01.
- **Role:** IL36A and IL36G are keratinocyte-derived IL-1-family cytokines that drive NF-κB- and MAPK-dependent inflammation; IL36RN is the receptor antagonist.
- **Relationship:** IL36A/G are ligands; IL36RN is a receptor antagonist. This is a regulatory interaction at the receptor level, not direct binding between IL36RN and the ligands.
- **Evidence:** Direct input dataset; pathway/ontology evidence; disease-association and genetic evidence for IL36RN in pustular psoriasis.

### 2. IL-20 family cytokines: IL19, IL20, IL26

- **Direction:** IL19 +7.58, IL20 +5.67, IL26 +4.36.
- **Role:** IL-20 family cytokines signal through IL-20 receptor complexes and STAT3, promoting keratinocyte proliferation and antimicrobial responses.
- **Relationship:** These cytokines share receptor subunits and downstream signaling. They are pathway co-members, not direct binding partners of one another.
- **Evidence:** Direct input dataset; strong published disease-association evidence.

### 3. S100/defensin antimicrobial effector module

- **Direction:** S100A7A +9.83, S100A7 +7.09, S100A8 +7.73, S100A12 +8.33, DEFB4A +11.18, DEFB4B +11.03, DEFB103A/B +5.75, PI3 +9.24, TCN1 +8.04.
- **Role:** Antimicrobial peptides and alarmins; chemoattract and activate neutrophils; contribute to the innate immune barrier.
- **Relationship:** Co-expressed and co-regulated by IL-17/IL-36. S100 proteins can form dimers, but no direct physical interaction between S100 proteins and defensins is established from this dataset. Their relationship is best described as co-expression and pathway co-membership.
- **Evidence:** Direct input dataset; disease-association and expression evidence. Caveat: some of these genes may be neutrophil-derived.

### 4. Cornified envelope module: SPRR2A/B/D/E/F/G, SPRR3, LCE3A/D

- **Direction:** Log2FC roughly +4 to +8.
- **Role:** Structural components of the cornified envelope; upregulation indicates active epidermal barrier remodeling.
- **Relationship:** SPRRs and LCEs are substrates for transglutaminase-mediated cross-linking during cornification. This is a known biochemical/direct interaction within the cornified envelope, but the current dataset only shows co-expression.
- **Evidence:** Direct input dataset; pathway/ontology evidence; keratinocyte differentiation literature.

### 5. Protease/anti-protease module: SERPINB3/B4/B11/B13, KLK13, TMPRSS11D

- **Direction:** SERPINB3 +6.74, SERPINB4 +9.12, SERPINB11 +4.47, SERPINB13 +3.09, KLK13 +4.05, TMPRSS11D +7.75.
- **Role:** Regulate proteolytic activity in epidermis, desquamation, inflammation, and apoptosis.
- **Relationship:** SERPINs are protease inhibitors, and KLK/TMPRSS proteases are potential targets. However, direct pairing between specific SERPINs and KLK13/TMPRSS11D is not established by these data. This is best described as a putative protease–inhibitor network.
- **Evidence:** Direct input dataset; protein-family evidence; limited direct interaction evidence. Needs functional validation.

### 6. Lipid/eicosanoid module: PLA2G4D, PLA2G4E, AKR1B10, AKR1B15, FABP5, ABCG4

- **Direction:** All upregulated, with log2FC from +2.47 to +6.27.
- **Role:** Phospholipid hydrolysis, fatty-acid transport, lipid mediator generation, retinoid/carbonyl metabolism.
- **Relationship:** PLA2G4D/E generate lipid precursors; FABP5 binds and transports fatty acids; AKR1B10/15 metabolize reactive carbonyls/retinoids. These are metabolic pathway co-memberships, not direct physical interactions.
- **Evidence:** Direct input dataset; known lipid-inflammatory biology; moderate disease-association evidence.

### 7. Proliferation module: CCNE1, RRM2, CDK5R1

- **Direction:** CCNE1 +2.56, RRM2 +2.72, CDK5R1 +2.35.
- **Role:** DNA replication and cell-cycle progression; consistent with keratinocyte hyperplasia.
- **Relationship:** CCNE1–CDK2 and RRM2 are part of the cell-cycle machinery, with RRM2 an E2F target. CDK5R1 is a CDK5 activator and may not belong to the canonical cell-cycle pathway; its inclusion is more speculative.
- **Evidence:** Direct input dataset; psoriasis-associated hyperplasia; unclear cell source.

### 8. Immune recruitment/checkpoint module: CD274, CXCL13, CXCR2, PRKCQ, ADAP2

- **Direction:** CD274 +3.44, CXCL13 +5.89, CXCR2 +2.70, PRKCQ +2.88, ADAP2 +2.09.
- **Role:** CD274/PD-L1 is an immune checkpoint ligand; CXCL13 is a B-cell/T-follicular-helper chemoattractant; CXCR2 supports neutrophil chemotaxis; PRKCQ/PKC-θ is required for T-cell activation.
- **Relationship:** These genes co-occur in an inflamed immune microenvironment, but they reflect different cell populations. There is no direct molecular interaction among them in this dataset.
- **Evidence:** Direct input dataset; literature evidence. Caution: cell-composition effects are likely.

### 9. WNT5A

- **Direction:** +2.53.
- **Role:** Noncanonical Wnt ligand implicated in inflammation and keratinocyte behavior.
- **Relationship:** No direct interaction with the other major genes can be inferred from this dataset. It may participate in inflammatory/proliferative crosstalk, but this is a putative pathway-level relationship.
- **Evidence:** Direct input dataset; published psoriasis-association evidence. This is a supported hypothesis, not an established mechanistic module.

### 10. Downregulated module: BTC, CYP2W1, UGT3A2, WAKMAR1, LOC107984452

- **Direction:** Downregulated, log2FC approximately −4 to −6.
- **Role:** BTC encodes an EGFR ligand; CYP2W1 and UGT3A2 encode metabolic enzymes; WAKMAR1 is a lncRNA. The functional interpretation of this module is unclear.
- **Relationship:** Co-downregulation may reflect suppression of normal epidermal metabolic/differentiation programs, but there is no evidence of direct interaction.
- **Evidence:** Direct input dataset only. This module should be considered **insufficient evidence** for a specific biological program until functionally characterized.

---

## 4. Validation priorities

### 1. Cell-type localization and composition check

**Category:** Confounding / composition check

**Why:** The dataset is from bulk skin. Strong signals such as S100A12, PI3, TCN1, CXCR2, CXCL13, and PRKCQ could largely reflect infiltrating neutrophils and lymphocytes rather than keratinocyte expression.

**Current evidence:** All genes are highly differentially expressed, but the dataset provides no spatial or single-cell resolution.

**External evidence:** Existing single-cell and spatial transcriptomic studies of psoriasis show that keratinocytes, T cells, and myeloid cells each contribute distinct transcriptional programs.

**Next step:** Perform single-cell RNA-seq or spatial transcriptomics on paired lesional and normal skin; validate key proteins by multiplex immunostaining for IL36A, S100A12, SPRR2A, CD274, and CD3/neutrophil markers.

**Conclusion:** Supported hypothesis that composition contributes; cell-type assignment remains exploratory.

---

### 2. Functional dissection of the IL-36/IL-20 amplification loop

**Category:** Mechanistic hypothesis

**Why:** IL36A, IL36G, IL36RN, IL19, IL20, and IL26 are among the most strongly upregulated genes and are directly relevant to psoriasis pathogenesis.

**Current evidence:** Strong co-upregulation of agonists and the antagonist IL36RN suggests a regulated but active cytokine axis.

**External evidence:** IL36RN mutations cause generalized pustular psoriasis; IL-36 receptor blockade is clinically active in pustular psoriasis. IL-20 family cytokines are known to activate STAT3 in keratinocytes.

**Next step:** In keratinocyte or organotypic skin models, stimulate with IL-17/TNF/IL-36 and perturb IL36A/IL36G/IL36RN or IL-20 receptor signaling; measure downstream S100/defensin, cornified envelope, and proliferation genes.

**Conclusion:** Supported hypothesis; causal direction is not established by the current transcriptomic data.

---

### 3. PLA2G4D/eicosanoid lipid-mediator axis

**Category:** Therapeutic target

**Why:** PLA2G4D and related lipid genes are strongly upregulated and represent a druggable enzymatic pathway distinct from cytokine signaling.

**Current evidence:** PLA2G4D, PLA2G4E, AKR1B10, AKR1B15, FABP5, and ABCG4 are all upregulated.

**External evidence:** PLA2G4D is expressed in psoriatic epidermis and can generate pro-inflammatory eicosanoids/oxylipins. Inhibitors of phospholipase A2 enzymes exist, but their efficacy in psoriasis is not established.

**Next step:** Measure lipid mediators in lesional skin; test PLA2G4D inhibition in psoriasis-like organotypic keratinocyte models or imiquimod-induced inflammation models.

**Conclusion:** Exploratory hypothesis. Expression change alone is not sufficient to claim therapeutic target status.

---

### 4. Protease/anti-protease imbalance: SERPINs, KLK13, TMPRSS11D

**Category:** Mechanistic hypothesis

**Why:** Multiple protease inhibitors and proteases are simultaneously upregulated, suggesting an important but poorly understood balance.

**Current evidence:** SERPINB3/B4/B11/B13, KLK13, and TMPRSS11D are all strongly upregulated.

**External evidence:** Kallikrein-related peptidases regulate desquamation; SERPINB3/B4 are markers of squamous differentiation and can inhibit cathepsin-like proteases. Specific pairing with KLK13/TMPRSS11D is not established.

**Next step:** Use activity-based proteomics and protease-substrate screening; knock down KLK13 or TMPRSS11D in epidermal models and assess desquamation, cytokine release, and barrier function.

**Conclusion:** Exploratory hypothesis.

---

### 5. Spatial immune microenvironment: CD274, CXCL13, CXCR2, PRKCQ

**Category:** Interaction / network hypothesis

**Why:** The co-upregulation of immune checkpoint, chemokine, and T-cell activation genes suggests an organized immune microenvironment, but the relationship among these components is unclear.

**Current evidence:** CD274, CXCL13, CXCR2, and PRKCQ are co-upregulated in lesional skin.

**External evidence:** CD274/PD-L1 can be induced by IFN-γ in keratinocytes; CXCL13 is associated with lymphoid aggregates; PKC-θ is important for Th17 cell activation.

**Next step:** Use multiplex imaging or spatial transcriptomics to map CD274+ cells relative to PD-1+ T cells, CXCL13+ B cells, and CXCR2+ neutrophils in the same tissue sections.

**Conclusion:** Supported hypothesis that the lesion is immunologically active; the specific network interactions are exploratory.

---

## 5. Evidence grounding

The interpretations above rely on several evidence categories:

- **Direct evidence from the input dataset:** Differential expression with extremely small FDR values for all genes discussed.
- **Pathway/ontology evidence:** Known Reactome, GO, and KEGG annotations for keratinization, IL-36 signaling, antimicrobial peptides, cell cycle, and lipid metabolism.
- **Protein interaction/regulatory evidence:** IL36RN antagonism of the IL-36 receptor is known; SPRR/LCE cross-linking in the cornified envelope is known. However, these interactions are not proven by the current dataset.
- **Disease-association evidence:** IL-36/IL-17/IL-20 signaling, S100/defensin upregulation, and epidermal hyperplasia are established features of psoriasis.
- **Expression/tissue-specific evidence:** Some genes are known to be expressed in keratinocytes or infiltrating immune cells, but bulk tissue data cannot resolve this.
- **Genetic/clinical evidence:** IL36RN mutations are linked to pustular psoriasis; this supports the importance of the IL-36 pathway but does not directly validate the current transcriptomic result as causal.
- **Drug/therapeutic evidence:** The existence of IL-36 receptor or JAK inhibitors does not by itself prove that the corresponding genes are therapeutic targets in plaque psoriasis. This dataset provides expression evidence only.

These evidence categories are not fully independent. Pathway annotations, disease-association databases, and published literature partly overlap. The strongest conclusions are those supported by multiple independent gene families within the input dataset and known biological coherence, such as the IL-36/IL-20/antimicrobial peptide axis. The weakest conclusions are those based on single unvalidated genes or poorly annotated lncRNAs.

---

## 6. Limitations and alternative explanations

### 1. Tissue and cell-composition differences

Bulk lesional skin contains hyperplastic keratinocytes, T cells, neutrophils, dendritic cells, and altered fibroblasts. Many of the strongest signals, including S100A12, PI3, TCN1, and CXCR2, may be driven in part by neutrophil infiltration. Conversely, downregulated genes such as BTC and UGT3A2 may reflect reduced numbers of certain normal skin cell populations. This can be addressed by single-cell RNA-seq, spatial transcriptomics, and cell-type deconvolution.

### 2. Disease severity, treatment exposure, and lesion site

The clinical metadata are not available. Psoriasis severity, current or previous topical/systemic treatment, biopsy site, and lesion stage strongly influence gene expression. The extremely low FDR values indicate statistically robust differences in this cohort, but the generalizability and effect sizes may vary across clinical contexts.

### 3. Association versus causation

This is a cross-sectional transcriptional comparison. Upregulation of IL36RN, CD274, and TNIP3 may represent negative feedback, while upregulation of S100/defensins may be a downstream consequence rather than a driver. The data cannot distinguish cause, consequence, or compensatory response. Functional perturbation is required.

### 4. Broad or nonspecific pathway enrichment

Several programs, particularly antimicrobial peptides, cornified envelope genes, and cell-cycle genes, are also active in wound healing, atopic dermatitis, and other inflammatory or hyperproliferative skin conditions. These findings are consistent with psoriasis but are not necessarily diagnostic or disease-specific without direct comparator groups.

### 5. Technical and annotation limitations

No platform, batch, or covariate information was provided. Although FDR values are extremely low, hidden batch effects or sample quality differences could inflate confidence. In addition, several differentially expressed loci are unannotated or poorly characterized (e.g., LOC105376238, LOC107984452, LINC01206, WAKMAR1). Their biological roles remain insufficiently understood.

---

## Final conclusion

The current dataset provides high-confidence evidence that psoriatic lesional skin is characterized by a coordinated upregulation of IL-36/IL-20 family cytokines, S100/defensin antimicrobial effectors, cornified envelope/keratinocyte differentiation genes, and cell-cycle/proliferation genes, with a less prominent set of downregulated normal epidermal metabolic genes. The most defensible interpretation is that this transcriptome reflects the IL-17/IL-36/IL-20-driven keratinocyte–immune amplification loop and regenerative epidermal hyperproliferation. However, causal direction, cell-source assignment, and translational relevance require direct validation by single-cell/spatial methods and functional experiments.
